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Abstract
Background: Palmoplantar pustulosis is a rare but painful and debilitating disease. It consistently ranks the highest
of all psoriasis phenotypic variants in terms of symptoms and functional impairment. Management of plaque-type
psoriasis has been revolutionised in the last 10 years with the advent of biologic therapies, but treatment options
for pustular psoriasis remain profoundly limited. On the basis of mechanistic findings which suggest a key pathogenic
role for interleukin (IL)-1 in pustular psoriasis, we hypothesise that anakinra (IL-1 blockade) will be an efficacious
treatment for pustular psoriasis.
Methods/design: We will conduct a two-stage, adaptive, double-blind, randomised, placebo-controlled trial to
test the hypothesis that anakinra, self-administered daily by subcutaneous injection over 8 weeks, will deliver
therapeutic benefit in palmoplantar pustular psoriasis, a localised form of pustular psoriasis typically involving
the palms and/or soles. Safety outcomes will be collected for 20 weeks. A total of 64 participants will be randomised to
anakinra or placebo in a 1:1 ratio. At the end of stage 1, a decision to progress to stage 2 will be made. This decision
will take place after 24 participants have been randomised and followed for 8 weeks and will be based on the ordering
of the observed mean outcome values in both treatment arms. At the end of stage 1, the reliability of
outcome measurements and method to collect the data will also be assessed, and the primary outcome
will be confirmed for stage 2.
Discussion: We have undertaken an adaptive approach in which we will gain proof-of-concept data prior
to completing a powered efficacy trial because pustular psoriasis is a rare disease, no validated outcome
measures to detect change exist, and limited safety data for anakinra exist in this population. To our knowledge,
this will be the first randomised controlled trial that will provide valuable evidence for the efficacy and safety of
IL-1 blockade for treatment in pustular psoriasis.
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Background
Pustular psoriasis is characterised by painful, intensely
inflamed red skin studded by sheets of monomorphic,
sterile, neutrophilic pustules. It may be generalised
(generalised pustular psoriasis [GPP]) or localised to
the palms and/or soles (palmoplantar pustulosis [PPP])
or nail apparatus (Acrodermatitis continua of Hallo-
peau) [1]. It consistently ranks the highest of all psoria-
sis phenotypic variants in terms of symptoms [2] and
functional impairment [3], so that the consequent im-
pact is great and equivalent to major medical and psy-
chiatric illnesses [2, 4]. Management of plaque-type
psoriasis has been revolutionised in the last 10 years
with the advent of biologic therapies driven in great
part by the scientific discovery of underlying genetic
and immunological disease pathways [5]. In contrast,
treatment options for pustular psoriasis are profoundly
limited. Other than one small randomised controlled
trial (RCT) involving ustekinumab in PPP (n = 33) [6],
no relevant interventional trials have been published
since 2001 [7]. Topical therapy is useful for a minority
of cases with mild disease. A Cochrane review of inter-
ventions for PPP [8] found evidence for the use of sys-
temic retinoids, a drug class with unpleasant dose-
limiting mucocutaneous side effects in most people and
of teratogenic potential. The authors of the review also
found benefit for oral psoralen and ultraviolet A
(PUVA) therapy, an intervention for short-term use
that necessitates concomitant oral or topical psoralen
and twice-weekly attendance for treatment and which
carries a risk of skin cancer. Ciclosporin is only to be
‘considered’ [7], owing to a paucity of evidence, and
should not be used beyond 1 year, owing to nephrotox-
icity. Tumour necrosis factor (TNF) antagonists, used
to great benefit in chronic plaque psoriasis, are largely
ineffective [9]. There is thus a significant unmet need
for effective treatments with acceptable safety profiles
for this patient group.
The poor response in pustular psoriasis to therapies
used to great effect in plaque-type disease may be ex-
plained by recent evidence indicating that molecular
pathways underlying pustular psoriasis are distinct and
involve the interleukin (IL)-36/IL-1 axis. Functionally
relevant IL36RN mutations in both GPP and localised
forms have been identified [10–12]. IL36RN encodes
the IL-36 receptor antagonist (IL-36Ra), an IL-1 family
member that antagonises the pro-inflammatory activity
of IL-36 cytokines. Disease mutations disrupt the in-
hibitory function of IL-36Ra, causing enhanced produc-
tion of downstream inflammatory cytokines, including
IL-1 [11, 12]. In keeping with these findings, patients
with IL36RN mutations significantly upregulate IL-1
production in response to IL-36 stimulation [11]. Re-
gardless of IL36RN mutation status, the peripheral
blood mononuclear cells of patients with localised pus-
tular psoriasis over-express at least three genes [13, 14]
that are consistently up-regulated in IL-1-mediated
conditions. These findings suggest a key pathogenic
role for IL-1, a cytokine that is known to sustain the in-
flammatory responses initiated by skin keratinocytes.
Given the proven therapeutic effect of IL-1 antago-
nists in the treatment of IL-1-mediated diseases, many
of which feature neutrophilic infiltration of the skin, we
hypothesise that IL-1 blockade will deliver therapeutic
benefit in pustular forms of psoriasis. Early proof-
of-concept data support this hypothesis: Anakinra, a
highly effective IL-1Ra, produced complete and rapid
resolution of pustules within days in patients with gen-
eralised [15–17], (n = 4, including 3 with and 1 without
IL36RN mutations) and localised disease [18, 19] (n = 3,
including 2 without IL36RN mutations). In two patients
with disease relapse on stopping anakinra, pustules
cleared on restarting therapy.
Because existing proof-of-concept data for anakinra
are limited, in this trial we will first obtain further evi-
dence for benefit and safety prior to completing a fully
powered efficacy trial. The study population will be
adults with palmoplantar pustulosis (PPP) as the clin-
ical paradigm for all forms, given that it causes very
significant disability in its own right, is the most com-
mon form, and features chronic development of
pustules. Because there are no validated outcome mea-
sures of disease change for pustular psoriasis and exist-
ing measures include a subjective component, two
‘candidate’ outcome measures will initially be trialled in
four centres prior to expanding to the wider multi-
centre study.
We will use a two-stage, adaptive, double-blind, rando-
mised, placebo-controlled trial to test our hypothesis
that IL-1 blockade with anakinra will deliver therapeutic
benefit in pustular forms of psoriasis. At the end of stage
1, a decision to progress to stage 2 to complete the pow-
ered efficacy trial will be made on the basis of ordering
of the observed mean outcome values in both treatment
arms. At this stage, the reliability of measurements and
method to collect the data will also be assessed, and the
primary outcome will also be confirmed.
Methods/design
This protocol has been prepared and reported in ac-
cordance with the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) guidance
[20]. The trial SPIRIT checklist can be viewed in
Additional file 1.
Primary objective
Our primary objective in this trial is to determine the ef-
ficacy of anakinra as a treatment for adults with PPP
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compared with placebo. Using a two-stage adaptive
design, we will obtain proof of concept prior to com-
pleting a fully powered efficacy trial. At the end of
stage 1, a decision to STOP or GO to stage 2 will be
made, the primary outcome measure will be verified,
and safety outcomes will be assessed. The default pri-
mary outcome will be fresh pustule count unless Pal-
moplantar Pustulosis Psoriasis Area and Severity
Index (PPPASI) is assessed to be a more reliable and
appropriate measurement.
Secondary objectives
1. To estimate the treatment effect of anakinra in
PPP as indicated by change in disease activity
over 8 weeks, adjusted for baseline, compared
with placebo using PPPASI or pustule count
2. To estimate the time to response of PPP (defined as
a 75% reduction in fresh pustule count) and relapse
rate (defined as return to baseline fresh pustule
count) with anakinra compared with placebo
3. To estimate the proportion of randomised patients
who achieve clearance of PPP with anakinra
compared with placebo by 8 weeks
4. To estimate any treatment effect of anakinra in
pustular psoriasis at non-acral sites as measured by
percentage area of involvement at 8 weeks
5. To estimate any treatment effect of anakinra in
plaque-type psoriasis (if present) measured using
Psoriasis Area and Severity Index (PASI) at
8 weeks
6. To assess adverse event (AE) data to evaluate the
harm profile of anakinra
7. To estimate the impact of anakinra on patients’
symptoms and quality of life
8. To estimate the proportion of randomised patients
who find the treatment acceptable or ‘worthwhile’
9. To estimate the proportion of randomised patients
who adhere to treatment
Trial design
APRICOT (Anakinra for pustular psoriasis trial) is a
small population, randomised, double-blind, placebo-
controlled, multi-centre study with two stages, including
a pre-specified adaptive element. The trial will test the
superiority of anakinra in PPP. Sixty-four participants
will be randomised to either of two parallel arms, as
depicted in Fig. 1. Stage 1 will include approximately 4–
8 centres (NHS clinics), and the interim analysis will be
performed after 24 participants have been randomised
and followed for 8 weeks. At this time point, the deci-
sion to continue to stage 2, confirmation of the primary
outcome and assessment of safety will be made by the
independent data monitoring committee (IDMC). The
study design can be seen in Fig. 2.
Decision 1
STOP: Placebo arm does as well as or better than treat-
ment arm for both of the two outcomes; that is, the
point estimates are the same, or the point estimate in
placebo is less than the treatment arm for fresh pustule
count and PPPASI.
GO: Treatment arm does better than placebo arm for
at least one measure; that is, the point estimate for the
treatment arm is lower than in the placebo arm for at
least one of fresh pustule count and PPPASI.
Assuming the GO criteria are achieved, the IDMC
will review all safety data from stage 1 and any new
drug safety data available through the drug manufac-
turer and supplier Swedish Orphan Biovitrum (SOBI)
or other sources.
Decision 2
If the outcome of decision 1 is to progress to stage 2,
the primary outcome for stage 2 will then be verified.
By default, the primary outcome will be fresh pustule
count unless PPPASI is assessed to be more reliable
and discriminating.
Two statistical analysis plans (SAPs) will be developed.
The stage 1 SAP will include a guide to aid the formal
decision-making process. The stage 2 SAP will be devel-
oped on completion of stage 1 and will detail the full
trial analysis. Stage 1 will include approximately 4–6
centres and will take place after 24 participants have
been randomised and have completed 8 weeks of
follow-up. Stage 2 will include approximately 15–20 cen-
tres and a further 40 participants.
Study population
Our study population will be adults with PPP requiring
systemic therapy.
Inclusion criteria
1. Adults (aged ≥ 18 years) with a diagnosis of PPP
made by a trained dermatologist with disease of
sufficient impact and severity to require systemic
therapy
2. Disease duration > 6 months, not responding to an
adequate trial of topical therapy including very
potent corticosteroids
3. Evidence of active pustulation on palms and/or
soles to ensure sufficient baseline disease activity
to detect efficacy
4. At least moderate palmoplantar pustulosis as
measured using the Investigator’s Global
Assessment (PPP-IGA)
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Exclusion criteria
1. Previous treatment with anakinra or other IL-1
antagonists
2. A history of recurrent bacterial, fungal or viral
infections
3. Evidence of active infection or latent tuberculosis or
seropositive for human immunodeficiency virus,
hepatitis B virus or hepatitis C virus
4. A history of malignancy of any organ system within
the past 5 years
5. With moderate renal impairment (CrCl < 50 ml/
min), neutropenia (< 1.5 × 109/L) or thrombocytopenia
(< 150 × 109/L)
6. Known moderate hepatic disease and/or raised
hepatic transaminases (alanine transaminase/
aspartate transaminase) more than twice the
upper limit of normal at baseline
Fig. 1 Study flow of participants in APRICOT
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Fig. 2 Diagram depicting study design and flow of participants. Decision 1: If placebo does as well or better than treatment arm for both
of the two outcomes, Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI) or fresh pustule count, the study will STOP. If the
treatment arm does better than the placebo arm for at least one outcome the study will proceed (GO). These decisions will be made on
the basis of the mean outcome values for each arm. Decision 2: Choice of the primary outcome. If the trial continues (‘GO’), the choice
of the primary outcome will by default be the fresh pustule count. If the PPPASI is determined to be more reliable and discriminating
than the fresh pustule count then the primary outcome will be PPPASI. ITT Intention to treat
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7. Live vaccinations within 3 months prior to the start
of study medication
8. Women who are pregnant, breastfeeding or of
childbearing age not on adequate contraception,
or men planning conception
9. Poorly controlled diabetes mellitus, cardiovascular
disease or asthma, or concomitant therapy that may
interact with anakinra
10. Unable to given written informed consent or comply
with the study visit schedule
Participation will also be excluded if there is use of
therapies with potential or known efficacy in psoriasis
during or within the following specified time frames
before treatment initiation:
1. Very potent topical corticosteroids within 2 weeks
2. Topical treatment that is likely to impact signs and
symptoms of psoriasis within 2 weeks e.g.
corticosteroids, vitamin D analogues, calcineurin
inhibitors, retinoids, keratolytics, tar, urea
3. Methotrexate, ciclosporin, acitretin, alitretinoin
within 4 weeks
4. Phototherapy or PUVA therapy within 4 weeks
5. Etanercept or adalimumab within 4 weeks
6. Infliximab or ustekinumab or secukinumab within
3 months
7. Other TNF antagonists within 3 months
8. Other immunosuppressive or immunomodulatory
therapy within 30 days or 5 half-lives prior to
treatment initiation, whichever is longer
9. Any other investigational drugs within 30 days
(or 3 months for investigational monoclonal
antibodies) or 5 half-lives prior to treatment
initiation, whichever is longer
Intervention
The active arm will receive anakinra (Kineret; SOBI,
Stockholm, Sweden) 100 mg/0.67 ml daily through
self-administered subcutaneous injection. SOBI will sup-
ply the investigational medicinal in pre-filled syringes.
The control arm will receive identical matched syringes
containing 0.67 ml of vehicle solution only. Each patient
will self-administer a daily subcutaneous injection of in-
vestigational medicinal product (anakinra or placebo) for
8 weeks and will be followed for 12 weeks post-random-
isation with a final safety follow-up visit at approxi-
mately 20 weeks (90 days after last trial treatment).
Adherence and concomitant medication
Participants will receive daily text reminder messages to
encourage them to comply with the daily dosing sched-
ule and will be asked to respond to the text to confirm
that they have taken their medication. Those patients
who are unable to provide a mobile phone number for
text reminders or do not wish to will be asked at each
visit for a record of their daily injections.
Permitted medications include topical therapy such
as hydrocortisone, antihistamine for injection site reac-
tions, and mild topical corticosteroids for the treatment
of psoriasis at sites other than hands and feet. The use
of a potent corticosteroid as ‘rescue’ topical therapy will
be dispensed and recorded by the study team. Very po-
tent topical corticosteroids (e.g., clobetasol propionate
0.05%), along with any topical treatment likely to im-
pact signs and symptoms of PPP, are prohibited.
Outcomes
The primary outcome will be confirmed at the end of
stage 1 and will be as follows:
1. Fresh pustule count on palms and soles across 1, 4
and 8 weeks (adjusted for baseline fresh pustule
count on palms and soles)
The count will include pustules macroscopically visible,
white/yellow in colour with no brown colour, and present
on the glabrous skin of the palms and/or soles.
OR
2. PPPASI across 1, 4 and 8 weeks (adjusted for
baseline PPPASI)
The PPPASI has been adapted from the PASI by
Bhushan et al. [21] and has been used as the primary out-
come measure in previous trials evaluating interventions
in PPP [6, 8].
Secondary outcomes
Investigator-assessed efficacy measures will be as follows:
1. Fresh pustule count on palms and soles OR
PPPASI, depending on the primary outcome
confirmed at stage 1
2. Total pustule count (pustules must be macroscopically
visible, white/yellow/brown in colour, with or without
crust) on palms and soles across weeks 1, 4 and
8 adjusted for baseline
3. PPP-IGA at weeks 1, 4 and 8 adjusted for baseline
(clear, almost clear, mild, moderate, severe)
4. Time to response of PPP (a 75% reduction in fresh
pustule count)
5. Time to relapse (defined as return to baseline fresh
pustule count)
6. Time to achievement of ‘clear’ on PPP-IGA by
8 weeks
7. Development of a disease flare (> 50% deterioration
in PPPASI)
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8. Pustular psoriasis at non-acral sites (not hands and
feet) as measured by percentage area of involvement
at 8 weeks
9. Plaque-type psoriasis (if present) measured using PASI
at 8 weeks
Safety measures will include the following:
 Serious infection as defined by any infection
leading to death, hospital admission or requiring
intravenous antibiotics
 Neutropenia (neutrophil count of ≤ 1.0 × 109/L)
 All reported AEs, adverse reactions (ARs), unexpected
adverse reactions (UARs) and serious AEs, ARs
and UARs
Patient-reported efficacy outcomes are as follows:
 Patient’s global assessment (clear, nearly clear, mild,
moderate, severe, very severe) across 1, 4 and 8 weeks
 Palmoplantar Quality of Life Instrument score at
8 weeks [3]
 Dermatology Quality of Life Index at 8 weeks [22]
 EQ-5D-3L score at 8 weeks [23]
 Treatment acceptability (five questions, such as
whether the treatment is ‘worthwhile’) evaluated
using a brief questionnaire with a response scale
of 1–5 at week 12
 Adherence to treatment as measured by responses
to daily text messages over 8 weeks
The schedule of trial enrolment, interventions and as-
sessments is presented in Fig. 3. Primary outcome assess-
ments of fresh pustule count and PPPASI will be carried
out by an independent assessor blind to study treatment
at each site. During stage 1, a second assessor, blind to
treatment, will also assess PPPASI and PPP-IGA at each
site, and photography will be completed to enable a cen-
tral blinded assessor to evaluate fresh pustule count to in-
form decision 2 (primary outcome for stage 2).
Fig. 3 Study procedures of APRICOT. AE Adverse event, bHCG Beta human chorionic gonadotropin, BSA Body surface area, CXR Chest x-ray, DLQI
Dermatology Quality of Life Index, EQ-5D-3L Three-level version of EQ-5D instrument, HBV Hepatitis B virus, HCV Hepatitis C virus, HIV Human
immunodeficiency virus, IMP Investigational medicinal product, PASI Psoriasis Area and Severity Index, PPPASI Palmoplantar Pustulosis Psoriasis
Area and Severity Index, PPP-IGA Palmoplantar pustulosis as measured using the Investigator’s Global Assessment
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Statistical considerations
Randomisation and blinding
Participants will be randomised to treatment in a 1:1 al-
location ratio using blocked randomisation stratified by
centre via an online system to ensure allocation conceal-
ment. The study team, treating clinicians, independent
outcome assessors and participants will be blind to treat-
ment arm. The study statistician will be subgroup-blind
(analysing arms labelled as ‘A’ and ‘B’) and will not be in-
volved in the analysis at stage 1. The analysis at stage 1
will be undertaken by the second statistician, who will
be subgroup-blind during the analysis but unblinded at
data review. The IDMC will operate unblinded. A
24-hour code break and medical information system will
be used to unblind healthcare workers in case of an
emergency. The chief and principal investigators will be
told of incidents, and the trial statistician will be in-
formed at the analysis stage of the trial.
Sample size
Because the potential primary outcome at this stage is
unknown, the sample size has been calculated by refer-
ence to a standardised effect size. An effect size of 0.9
SD was chosen with consideration of the cost of the
drug and motivation for patients to adhere to treatment,
given the requirement for daily self-administered sub-
cutaneous injections. In addition, larger effect sizes have
been reported with oral retinoids [8, 24], a recom-
mended systemic intervention for pustular psoriasis. To
detect a difference of 0.9 SD with power 90% using a 5%
significance level, a sample size of 27 per arm would be
required. RCTs involving placebo arms [21, 8] have ob-
served withdrawal rates of < 5%. We aim to recruit 32
participants per arm (N = 64 in total), which will allow
for an approximate 15% withdrawal rate.
Stage 1 sample size
The sample size for stage 1 is based on correct ordering
of group means. We want a high probability of continu-
ing (‘GO’) if there is a true (conservative) difference in
means between the groups of 0.5 SD, in favour of the
treatment group. With 20 patients (n = 10 per arm), as-
suming a real difference of 0.5 SD, the probability that
the means for treatment arms will be correctly ordered
(i.e., treatment mean greater than placebo mean) is 0.85.
If two outcomes are assessed, each with an expected dif-
ference of 0.5 SD, then the overall probability of failing
to GO is (1 − 0.85)2 = 0.0225 (i.e., less than 3 in 100).
There is thus a minimal chance of failing to continue if
the treatment really is beneficial. If there is no treatment
benefit, the probability of not progressing to the next
stage is 0.25 based solely on these rules. Whilst this is
low, the balance of errors has been selected to allow op-
timal identification of treatment benefit and at most
could only be 0.5 under this design. Stage 1 does not
involve statistical tests. To ensure that 10 participants
contribute to each arm, the interim analysis for stage
1 will occur after 24 participants have been rando-
mised and followed.
Analysis
All analyses will be based on the intention-to-treat
principle and will include all participants in the treat-
ment arms to which they were allocated, regardless of
treatment subsequently received. A detailed SAP will be
written for stages 1 and 2 separately. The stage 1 SAP
will detail the analysis to assess the reliability and dis-
criminative ability of the two proposed primary out-
comes. The decision to continue to stage 2 will occur if
the point estimates for the mean fresh pustule count OR
mean PPPASI are greater in the active arm than in the
placebo arm. The point estimate for the mean will be
the baseline adjusted treatment group differences (aver-
aged over 1, 4 and 8 weeks for each patient), calculated
using linear regression. To guide the decisions at the
end of stage 1, a number of different descriptive analyses
will be performed: Outcome distributions will be plotted;
the standardised mean difference will be calculated by
time point; agreement between the ‘site’ assessors and
the central ‘photographic’ assessment will be assessed
using the method of Bland and Altman [25], allowing for
the multiple observations; and the intraclass correlation
coefficient will be calculated using a mixed effects ana-
lysis of variance. Stage 1 will also include a full review of
all safety data. These data will be presented in line with
the prior IDMC reports and will predominantly include
AEs tabulated by treatment arm coded at the preferred
term level for reporting. When useful, time-to-event
analyses will be undertaken to examine the difference in
time-to-event curves between the two arms, and the
hazard function will be plotted to assess consistency in
risk over time. No hypothesis testing will be undertaken
for AE outcomes.
At the end of stage 2, the treatment effect will be esti-
mated using a linear (Gaussian) mixed model on weeks
1, 4 and 8 data. Participant will be included as a random
intercept, with fixed effects for time, time-by-treatment
group interaction and baseline score of the primary out-
come. Centre will be included in the model as either a
random or fixed effect, depending on the total number
of centres recruiting to the study and the average num-
ber of participants recruited from each centre. The esti-
mated treatment effect at 8 weeks will be reported with
a 95% CI and corresponding p value as the primary out-
come. We will also report the treatment effect at weeks
1 and 4. The fresh pustule count and PPPASI profiles
will be plotted over time for individuals to examine lon-
gitudinal patterns and help determine the necessity of
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including a random intercept term in the model. A sen-
sitivity analysis will then be undertaken for the primary
analysis with adjustment for use of rescue medication.
The proportion of participants using rescue medication
and the amount used will be summarised by treatment
arm. The primary analysis will be repeated, including
12-week follow-up data. All treatment effect estimates
will be reported with 95% CIs, and a 5% significance
level will be used for the primary outcome test. Every ef-
fort will be made to obtain follow-up data for all partici-
pants, including those who stop treatment. The
analytical methods described above will employ max-
imum likelihood estimation and thus are efficient for
handling missing outcome data under a missing at ran-
dom (MAR) assumption. When required, sensitivity ana-
lyses will investigate the robustness of the results to the
MAR assumption.
Continuous secondary outcomes will be analysed using
the same modelling approach as specified above. Binary
outcome data will be analysed using logistic regression
models. Kaplan-Meier curves will be plotted for time to
response and time to relapse. A complementary log-log
model will be fitted to estimate the treatment effect for
the time-to-event outcomes. If the proportional hazards
assumption is not met, an alternative parameterisation
will be used or an alternative time-to-event model will
be sought.
Data management
Data will be managed using the MACRO database sys-
tem (InferMed, London, UK). This system is regulatory
compliant and will be maintained by the King’s Clinical
Trials Unit. It will be hosted on a dedicated secure ser-
ver within King’s College London. The quality assurance
manager (sponsor) will conduct internal audits to check
on compliance with International Conference on Har-
monisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use guidelines for good
clinical practice (GCP), meeting the requirements of the
Medicines and Healthcare products Regulatory Agency
(MHRA). The audits will also include laboratory activ-
ities according to an agreed audit schedule, taking into
consideration the 2009 MHRA guidelines for GCP in
the laboratory.
Trial oversight committees
The IDMC will be responsible for monitoring evidence
for treatment harm and reviewing all decisions made in
relation to the safety aspects of the study. The IDMC
will meet on initiation of the project and agree on the
type and frequency of meetings. They will review all data
at completion of stage 1 and advise on the decision to
stop or continue the trial based on the pre-specified cri-
teria and any emerging safety concerns. They will advise
on the primary outcome for the trial using the SAP for
stage 1 to guide their decision making.
The trial steering committee (TSC) will include an in-
dependent chair, two independent members, an inde-
pendent patient representative, the chief investigator and
at least one study statistician. The TSC will meet as re-
quired with invited observers from the Efficacy and
Mechanism Evaluation (EME) programme. The TSC is
the main decision-making body. It will have overall re-
sponsibility for scientific strategy and direction and has
ultimate responsibility for ensuring that the project’s
aims are delivered on time and within budget. Specific
roles, meeting frequency and timelines will be detailed
in the TSC Terms of Reference.
Discussion
The treatment options for PPP are limited, and this trial
will provide evidence on an efficacy and safety profile for
anakinra for short-term treatment (8-week treatment
period and efficacy evaluation with further efficacy data
collected at 12 weeks and safety data up to 20 weeks).
We were unable to take a conventional approach to the
design of the study, owing to several constraints: PPP is
a rare disease; limited safety data for anakinra exist; and
there is no validated outcome for PPP. Rather than not
undertake trials in small populations when it is not pos-
sible to use traditional approaches, there has been a call
to change our approach to and thinking about such
studies [26]. The size of the study means this trial will
be able to detect a benefit only if the true effect size is
fairly large. The limitation of not detecting a smaller ef-
fect size was made with consideration of the trade-off
between the minimum benefit felt necessary with the re-
quirement for daily self-administered subcutaneous in-
jections along with the cost of the drug, as well as
existing effect sizes observed in drug treatments in this
disease [8, 24]. This decision was made with input from
clinicians and patients. In addition to the limited sample
size owing to the small population, we also faced three
other obstacles: uncertainty around a suitable outcome
measure that could capture change in PPP disease, lack
of proof-of-concept data, and minimal safety informa-
tion for this drug in this population. Because we are ex-
tremely limited by the number of total participants we
can recruit, this led us to address these uncertainties in
the current trial by incorporating an interim trial with
the potential to stop the trial after 24 patients if the re-
sults flag concern for safety or if there is no signal for ef-
ficacy. We were unable to use a conventional approach
to the design of the interim stage because this would re-
sult in a prohibitively large sample size. It was deemed
reasonable to accept the higher-than-desired probability
for progressing if there is no true benefit in light of the
overall total sample size along with knowledge that the
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trial would be closely monitored and stopped for safety if
required. This study includes a parallel mechanistic evalu-
ation, so this study will allow collection of relevant mater-
ial designed to investigate underlying disease pathogenesis
which will be informative for future treatment develop-
ment and symptom control.
Trial status
The APRICOT trial received ethical approval on 1st April
2016. The first participant was enrolled on 21st September
2016, and the trial in still recruiting participants for stage
1 and has randomised 31 participants.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOCX 42 kb)
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